|
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - COTA |
| |
|
|
|
Stock and Other Ownership Interests - GenomiCare Biotechnology; Syapse; Sygnomics |
Consulting or Advisory Role - GenomiCare Biotechnology; Sygnomics |
Research Funding - Syapse |
Travel, Accommodations, Expenses - Syapse |
| |
|
|
Stock and Other Ownership Interests - Tempus |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Roche |
Research Funding - Flatiron Health |
Travel, Accommodations, Expenses - Flatiron Health |
| |
|
No Relationships to Disclose |
| |
Pallavi Shruti Mishra-Kalyani |
No Relationships to Disclose |
| |
|
Employment - ConcertAI; Syapse |
Stock and Other Ownership Interests - ConcertAI; Syapse |
Travel, Accommodations, Expenses - ConcertAI; Syapse |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca; IQVIA |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Avalere Health |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |